0

AN-9

INQUIRY Add to cart
For Research Use Only | Not For Clinical Use
CATAP122110536
CAS122110-53-6
Structure
MDL NumberMFCD00209896
Molecular Weight202.25
InChI KeyGYKLFBYWXZYSOW-UHFFFAOYSA-N
Description≥95% (HPLC)
SolubilityDMSO: ≥10 mg/mL
Assay≥95% (HPLC)
Colorcolorless to slightly yellow
Formoil
Size25MG
Storage Conditions−20°C
1

AN-9 (Titan)

Erole Hobdy, John Murren

Curr Opin Investig Drugs. 2004 Jun;5(6):628-34.

PMID: 15242252

1

Butyric Acid and Pivaloyloxymethyl Butyrate, AN-9, a Novel Butyric Acid Derivative, Induce Apoptosis in HL-60 Cells

Y Zimra, L Wasserman, L Maron, M Shaklai, A Nudelman, A Rephaeli

J Cancer Res Clin Oncol. 1997;123(3):152-60.

PMID: 9119880

1

Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016

GBD 2016 Risk Factors Collaborators

Lancet. 2017 Sep 16;390(10100):1345-1422.

PMID: 28919119

1

Histone Deacetylase Inhibitors: The Anticancer, Antimetastatic and Antiangiogenic Activities of AN-7 Are Superior to Those of the Clinically Tested AN-9 (Pivanex)

Nataly Tarasenko, Abraham Nudelman, Igor Tarasenko, Michal Entin-Meer, Daphne Hass-Kogan, Aida Inbal, Ada Rephaeli

Clin Exp Metastasis. 2008;25(7):703-16.

PMID: 18506586

1

The Histone Deacetylase Inhibitor AN-9 Has Selective Toxicity to Acute Leukemia and Drug-Resistant Primary Leukemia and Cancer Cell Lines

Ayse Batova, Li-en Shao, Mitchell B Diccianni, Alice L Yu, Tetsuya Tanaka, Ada Rephaeli, Abraham Nudelman, John Yu

Blood. 2002 Nov 1;100(9):3319-24.

PMID: 12384433

  • Verification code
Contact Us

Send Us a Request

What is your specific need? We will do everything we can to meet your expectations.
Online Inquiry

Online Inquiry

For any inquiry, question or recommendation, please call: or fill out the following form.

  • Verification code

Head Office

  • Tel:
  • Email:

Follow us on

qrcode